Related Experiment Video
Updated: Apr 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission
Xanthippe-Argyro Koutsoukou1, Evangelia Papadavid, Konstantinos Theodoropoulos
12nd Department of Dermatology and Venereology, Attikon University General Hospital, University of Athens, Medical School, Athens, Greece.
Abstract:
Erythrodermic psoriasis is a severe type of psoriasis associated with comorbidities and high mortality. Patients with erythrodermic psoriasis need hospitalization and systemic treatment. Conventional drugs and biologic agents may not manage to control refractory and complicated erythrodermic psoriasis resulting from treatment failure. Ustekinumab, a human monoclonal antibody against interleukin-12 and 23, seems to be an effective therapeutic option in erythrodermic psoriasis whenever other therapies have failed.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acne Infection
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
